Retatrutide

Triple Receptor Agonist | GLP-1 · GIP · Glucagon

Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company. It is classified as a triple agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously.

In Phase 2 clinical trials, retatrutide demonstrated statistically significant reductions in body weight among participants — with some cohorts achieving average reductions approaching 24% over 48 weeks — making it one of the most studied compounds in the current generation of metabolic peptide research.

Researchers studying metabolic signalling, energy homeostasis, and receptor pharmacology may find retatrutide of interest due to its multi-receptor mechanism and distinct pharmacokinetic profile relative to single or dual agonist compounds.

Supplied as lyophilised powder. Purity ≥99% by HPLC. Third-party Certificate of Analysis available — tested by Janoshik Analytical (Prague) and issued in Longev Peptides' name.

For research use only. Not for human consumption.